Photo by Rajasekhar R on Unsplash. Stock photograph for illustration.
By David L. Carpenter, BSN, RN | Health Content Works
You start a medication to help manage your weight. You expect your appetite to change. Our guide to changes in hunger and food noise explains how to describe a different kind of craving. Then you notice something you were not expecting: you do not seem as interested in having a drink.
That raises a reasonable question. Is the medication doing something, or is something else going on? And if it is affecting alcohol cravings, could it help someone whose drinking has become a problem?
Researchers are asking those questions, too. Human studies of semaglutide are encouraging, including trials published in 2026. But the details matter. A change in the desire to drink, a reduction in heavy drinking, and successful treatment of alcohol use disorder are different outcomes. We should be clear about which one a study actually measured.
First, a safety issue that cannot wait
If you drink heavily and regularly, do not assume that losing interest in alcohol makes it safe to stop abruptly on your own. Withdrawal can be life-threatening. Contact a healthcare professional before making a major change so they can assess your risk and arrange appropriate care. Do not devise your own withdrawal plan. A weight-management medication is not a substitute for withdrawal care. [1,2]
Shaking, sweating, nausea, or a racing heart after cutting back can be signs of withdrawal. Contact a healthcare professional right away or go to an emergency department if you suspect withdrawal. Seizures, hallucinations, severe confusion, fever, or an irregular heartbeat in this setting require emergency care: call 911 in the United States. Do not dismiss these as routine medication side effects. [2]
If low energy is another concern, our guide to fatigue during treatment can help you organize what to discuss with your clinician. It does not replace the urgent withdrawal guidance above.
Wegovy and Zepbound are different medications
Wegovy contains semaglutide. Zepbound contains tirzepatide. Current U.S. labeling for these products does not include alcohol use disorder as an indication. That matters when a headline starts sounding like a treatment recommendation. The trials below tested particular oral or injectable semaglutide regimens, not every product containing the drug. [3,4]
It also matters when the headline says “weight-loss drugs,” but the study tested only semaglutide. Evidence about one medication does not establish the same effect for another. If you take Zepbound, the semaglutide findings are interesting, but they cannot tell you what your own response will be.
A 2024 study of electronic health records associated semaglutide use with fewer newly recorded or recurrent alcohol use disorder diagnoses than comparator medications. Statistical matching made the groups more comparable, but could not remove every difference in who received treatment or how diagnoses were recorded. This was observational evidence, not proof that semaglutide prevented or treated the disorder. [5]
What the semaglutide studies found
A 2025 randomized trial followed 48 adults with alcohol use disorder who were not seeking treatment. Its primary question concerned drinking during a laboratory session. Semaglutide reduced the amount consumed and peak breath alcohol concentration, although only 25 participants had complete data for that analysis. The registered secondary measure of average drinks per calendar day did not significantly improve. Exploratory measures of weekly craving and drinks per drinking day improved; the number of drinking days did not. The nine-week trial used low injectable doses and could not establish lasting recovery. [6]
Those distinctions can sound fussy until you think about what they mean. Drinking less on an evening when you drink is different from drinking on fewer evenings. Both may matter to someone trying to change, but they are not interchangeable.
A 2026 trial at one center randomized 108 treatment-seeking adults with moderate-to-severe alcohol use disorder and obesity. Both groups received cognitive behavioral therapy alongside either weekly semaglutide injections or placebo for 26 weeks. The primary outcome was change in heavy-drinking days. The estimated reduction was 13.7 percentage points greater with semaglutide than placebo (95% confidence interval, 5.4 to 22.0 points). Eighty-eight participants completed treatment; the analysis included all 108 using statistical estimates for missing outcomes. Gastrointestinal side effects were more common with semaglutide. These findings concern medication alongside counseling in a specific population, not a universal benefit or proof of lasting effects after stopping. [7]
An eight-week 2026 trial at one U.S. center randomized 50 adults seeking treatment for moderate-to-severe alcohol use disorder to oral semaglutide or placebo. Its primary endpoint—craving after alcohol cues in a laboratory at week six—did not differ significantly between groups. Of two key secondary drinking measures during the final four weeks, heavy-drinking days favored semaglutide, but average drinks per calendar day did not. Exploratory measures, including everyday craving, also favored semaglutide. The researchers did not adjust for testing multiple outcomes, increasing the possibility of chance findings. [8]
The trial was small and brief. All participants had overweight or obesity, most were White, and drinking was self-reported. Some placebo participants may have recognized their assignment, which could affect results. These limits matter when considering how the findings might apply to other people. [8]
Taken together, these findings give researchers a reason to keep going. They also give us a reason to resist turning a promising result into a guarantee. The studies differed in participants, formulation, treatment setting, and follow-up. We cannot simply combine their best results and call that what everyone should expect.
Where does that leave Zepbound?
A 2026 case report described three people with obesity, type 2 diabetes, and alcohol-associated liver disease whose self-reported alcohol intake fell after starting tirzepatide. Only one had documented alcohol use disorder, and that person had previously received another medication to reduce drinking. There was no comparison group, and other health changes occurred alongside treatment. The report cannot establish that tirzepatide caused the reduction or predict benefit for people taking Zepbound. [9]
So, if your interest in alcohol changes while taking Zepbound, tell your prescriber. It is useful information. It is not a reason to raise the dose yourself, switch medications, or assume you now have treatment for an alcohol problem. The semaglutide results do not answer those questions for tirzepatide.
Less craving is worth noticing. It is not the whole picture.
Craving is the urge to drink. Drinks per drinking day describes quantity on days someone drinks; drinking days describes frequency. Heavy-drinking days counts days that meet a study’s specified intake threshold. These measures answer different questions. Improvement in one does not, by itself, establish remission from alcohol use disorder. The diagnosis involves a broader assessment of impaired control and alcohol-related problems. [1,6,7,8]
You do not need to turn your life into a research project. If you notice a change, jot down what changed and when. Was it the urge to drink? The amount you drank? How often you drank? Did the change happen around a medication start or dose change? Were you also feeling sick? Bring those observations to your appointment rather than trying to prove the medication was responsible.
Be equally honest if nothing changed. You have not failed a test because someone online lost interest in alcohol and you did not. A study describes what happened in a group. It cannot promise what will happen to you.
What to discuss with your prescriber
A straightforward way to start is: “Since starting this medication, my interest in alcohol has changed. Can we talk about what that means for me?” If drinking has been difficult to control, say that directly, too. You do not need a polished explanation.
Tell your clinician how much and how often you drink, what medications you take, and what treatment you already receive. Be clear about any previous withdrawal, especially seizures or severe confusion. Ask whether you need a separate alcohol assessment and what support fits your situation. Research on semaglutide does not replace established alcohol care. Do not stop an existing alcohol treatment because a weight-management medication seems to be helping.
Evidence-based alcohol care already exists. Depending on the person, it can include medications, behavioral treatment, or a combination. Care can begin with a primary care clinician or an addiction specialist; it does not always mean residential treatment. NIAAA’s Alcohol Treatment Navigator explains treatment options and how to look for qualified help. [10]
Keep medication side effects in the conversation as well. The Wegovy and Zepbound guides advise stopping the medication and contacting a healthcare professional right away for severe abdominal pain that does not go away, with or without vomiting; the pain may extend to the back. Persistent vomiting or diarrhea also deserves a call because dehydration can cause kidney problems. Do not explain away significant symptoms as evidence that the medication is “working.” [3,4]
There is room for hope and careful questions
It is reasonable to be interested in this research. It is also reasonable to want better answers before making treatment decisions. We need to know who benefits, how durable the effects are, and how these medications fit with established alcohol care.
For now, notice changes, describe them honestly, and bring them to the clinician who knows your health history. If alcohol is causing problems, you deserve help now. You do not have to wait for the next study to ask for it.
General educational information, not individualized medical advice. Prepared with AI assistance and reviewed by David L. Carpenter, BSN, RN.
Sources and further reading
Evidence checked: October 17, 2026. The Lancet trial was reviewed at abstract level. Access to some full texts was limited; verification of the oral semaglutide trial and tirzepatide case report included indexed passages from the original papers.
1. NIAAA. Treatment for Alcohol Problems: Finding and Getting Help.
2. MedlinePlus. Alcohol withdrawal. Reviewed January 1, 2025.
3. DailyMed. Wegovy medication guide.
4. DailyMed. Zepbound medication guide.
Correction to reference 5. Published June 18, 2024. doi:10.1038/s41467-024-49655-6.
10. NIAAA Alcohol Treatment Navigator. Types of Alcohol Treatment.
Leave a Reply